Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has ...

Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 6.5%. Looking ahead, ...

Vaccine stocks slid late Thursday as reports stated noted anti-vaccine politician Robert Kennedy Jr. will serve as the next ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...